- Oral presentation
- Open Access
Atherosclerosis endothelial activation quantification in vivo with fluorine magnetic resonance imaging and spectroscopy
© Pan et al.; licensee BioMed Central Ltd. 2014
- Published: 16 January 2014
- Magnetic Resonance Spectroscopy
- Endothelial Activation
- Mouse Aorta
- Endothelial Inflammation
- Immune Cell Recruitment
Endothelial activation is one of the necessary initial steps in the formation of atherosclerotic plaque that facilitates immune cell recruitment and retention. To image and quantify early markers of endothelial inflammation, we recently developed a multiplexing peptide-based targeting system for post-formulation functionalization of perfluorocarbon (19F) nanoparticles (PFC NP) that is intrinsically quantifiable at a binding site based on magnetic resonance spectroscopy. The approach is now demonstrated in vivo to detect and quantify VCAM-1 in ApoE-/- mouse aorta.
VCAM-1 targeted PFC NPs were generated through post-formulation strategy by using linker peptides. Specific targeting has been validated in vitro by using confocal imaging, 19F magnetic resonance spectroscopy (MRS), and magnetic resonance imaging (MRI). Quantification of endothelial activation in atherosclerosis has been investigated by using ApoE-/- and control C57-BL6 mice through MRS.
Specific targeting to VCAM-1 in vitro to mouse endothelial cells subjected to TNF-α stimulation was confirmed by confocal imaging and magnetic resonance imaging (MRI), and quantified by 19F magnetic resonance spectroscopy (MRS) (11.7T) in comparison to a 19F calibration standard. Next, ApoE-/- and control C57-BL6 mice (n ≥3/group) fed a western diet for 8 weeks, were injected i.v. with VCAM-1 targeted or non-targeted nanoparticles. After two hours, aortas were subjected ex vivo to MRS analysis (11.7T) which revealed a 4.6-fold increase in the amount of nanoparticles in aortas from the ApoE-/- mice receiving VCAM-1 targeted nanoparticles as compared with other groups (ApoE -/- mice: targeted vs non-targeted - 8.22 ± 4.4 vs 1.78 ± 1.2 × 105 NPs/mm2, p < 0.05; C57-BL6 mice: targeted vs non-targeted - 2.28 ± 1.24 vs 2.08 ± 0.98 × 107 NPs/mm2).
The use of 19F MRI/MRS together with a flexible and rapid postformulation approach to creating ligand targeted nanoparticulate contrast agents may enhance the efficiency and breadth of molecular imaging of atherosclerosis with MRI and enable quantification of selected biomarker molecules that are important early drivers of atherosclerosis.
HL-073646 and CA-119342 to S.A.W.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.